IRDOpus Genetics Inc.
Company Overview
Name
52W High
52W Low
Market Cap
Dividend Yield
Price/earnings
P/E
Dividends
No dividend
Sentiment
Score
Bullish
72
Low
Neutral
High
0
50
100
Trade Volume
Score
Neutral
50
Low
Neutral
High
0
50
100
Income Statement
Total Revenue
Operating Revenue
Total Gross Profit
Total Operating Income
Net Income
EV to EBITDA
EV to Revenue
Price to Book value
Price to Earnings
Additional Data
Selling, General & Admin Expense
Research & Development Expense
Total Operating Expenses
Other Income / (Expense), net
Total Other Income / (Expense), net
Total Pre-Tax Income
Earnings History
Estimated EPS
Reported EPS
N/ACompany Overview
Name
52W High
52W Low
Market Cap
Dividend Yield
Price/earnings
P/E
Dividends
No dividend
Sentiment
Score
Bullish
72
Low
Neutral
High
0
50
100
Trade Volume
Score
Neutral
50
Low
Neutral
High
0
50
100
Income Statement
Total Revenue
Operating Revenue
Total Gross Profit
Total Operating Income
Net Income
EV to EBITDA
EV to Revenue
Price to Book value
Price to Earnings
Additional Data
Selling, General & Admin Expense
Research & Development Expense
Total Operating Expenses
Other Income / (Expense), net
Total Other Income / (Expense), net
Total Pre-Tax Income
Earnings History
Estimated EPS
Reported EPS
N/AUpcoming Earnings
Company Info
CEO
George Magrath
Location
North Carolina, USA
Exchange
Nasdaq
Website
https://opusgtx.com
Summary
Opus Genetics, Inc.
Company Info
CEO
George Magrath
Location
North Carolina, USA
Exchange
Nasdaq
Website
https://opusgtx.com
Summary
Opus Genetics, Inc.
Be the first to know. We'll notify you when AI insights for IRD go live.
Community Research
Research from investors like you
Be the first to share your analysis on IRD
Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.
Symbol's posts
2 Ultra-Risky Stocks With 300%+ Upside Potential
2 Ultra-Risky Stocks With 300%+ Upside Potential
Investors chasing huge gains are piling into two high-risk biotech stocks that could surge if key clinical data succeeds. is developing gene therapies for inherited blindness analysts see massive upside if trials succeed. focuses on late-stage retinal disease treatments, with pivotal Phase 3 data coming next year. Big rewards only if outcomes go right. What's you take on this???
No more topics to show